c-erbB-2 and HercepTest Dilema
<< Previous Message | Next Message >>
From: | Dave Tacha <dtacha@ncal.verio.com> |
To: | "histonet@Pathology.swmed.edu" <histonet@Pathology.swmed.edu> |
Reply-To: | |
Date: | Tue, 06 Jul 1999 18:04:23 -0700 |
Content-Type: | text/plain; charset=us-ascii |
I am becoming confused about the FDA approval of Dako's HercepTest. I
am hearing all sorts of rumors:
I heard that you don't need to use the Dako detection system for the
patient to receive treatment.
I've heard that only 3+ staining validates treatment recommendation.
I've heard that 2+ and 3+ staining validates treatment recommendation.
I've heard that Zymed has a FDA approved c-erbB-2 antibody. What kind
of FDA approval, and can you substitute this antibody instead of using
Dako polyclonal antibody?
I've heard, if a pathologist does there own in-house study to validate
their method, they can substitute this procedure and the patient can
receive treatment; or they can screen with there antibody and validate
with Dako's HercepTest kit.
I would to get some feedback from some pathologist as well as from
anybody else who would like to respond. However, I would like to get at
the truth. I would like real data to support what the truth really is.
David Tacha HTL (ASCP)
<< Previous Message | Next Message >>